Lonza has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California, USA, from Roche for $1.2 billion. The deal was...
Lonza inaugurated its new facility at the Colmar, France site. The new Innovaform Accelerator will serve as a Center of Excellence for developing and innovating capsule...
Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and...
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine...
Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product...
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Lonza has appointed Wolfgang Wienand as its new CEO. He will join the company during the summer of 2024 and succeed Albert M. Baehny, who took on the additional...
